Omeprazole-d3-1
Based on 1 Customer Validation
Omeprazole-d3-1 is the deuterium labeled Omeprazole. Omeprazole-1 (H 16868) is an orally active H+,K+-ATPase inhibitor and a proton pump inhibitor. Omeprazole-1 competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole-1 inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole-1 inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole-1 alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole-1 aslo has neuroprotective and antibacterial effects.
For research use only. We do not sell to patients.
- Purity: 95.09%
- CAS No.: 934293-92-2
- Formula: C17H16D3N3O3S
- Molecular Weight:348.43
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 934293-92-2
-
Unlabeled Cas 73590-58-6
-
Appearance Solid
-
Molecular Weight 348.43
-
Formula C17H16D3N3O3S
-
Color Light brown to brown
-
SMILES
CC(C(OC)=C(C=N1)C)=C1CS(C(NC2=C3[2H])=NC2=C([2H])C([2H])=C3OC)=O
-
Synonyms
H 16868-d3-1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMF : ≥ 30 mg/mL (86.10 mM)
DMSO : ≥ 30 mg/mL (86.10 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : ≥ 5 mg/mL (14.35 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
[2]. Li XQ, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821-827. [Content Brief]
[3]. Udelnow A, et al. Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. PLoS One. 2011;6(5):e20143. [Content Brief]
[4]. da Mata AMOF, et al. Evaluation of mutagenesis, necrosis and apoptosis induced by omeprazole in stomach cells of patients with gastritis. Cancer Cell Int. 2022;22(1):154. Published 2022 Apr 18. [Content Brief]
[5]. Chamniansawat S, et al. Ultrastructural intestinal mucosa change after prolonged inhibition of gastric acid secretion by omeprazole in male rats. Anat Sci Int. 2021;96(1):142-156. [Content Brief]
[6]. Mori Y, et al. Class effects of proton pump inhibitors in preventing oxaliplatin-induced peripheral neurotoxicity. J Pharmacol Sci. 2025;159(4):279-282. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMF / DMSO | 1 mM | 2.8700 mL | 14.3501 mL | 28.7002 mL | 71.7504 mL |
| 5 mM | 0.5740 mL | 2.8700 mL | 5.7400 mL | 14.3501 mL | |
| 10 mM | 0.2870 mL | 1.4350 mL | 2.8700 mL | 7.1750 mL | |
| DMF / DMSO | 15 mM | 0.1913 mL | 0.9567 mL | 1.9133 mL | 4.7834 mL |
| 20 mM | 0.1435 mL | 0.7175 mL | 1.4350 mL | 3.5875 mL | |
| 25 mM | 0.1148 mL | 0.5740 mL | 1.1480 mL | 2.8700 mL | |
| 30 mM | 0.0957 mL | 0.4783 mL | 0.9567 mL | 2.3917 mL | |
| 40 mM | 0.0718 mL | 0.3588 mL | 0.7175 mL | 1.7938 mL | |
| 50 mM | 0.0574 mL | 0.2870 mL | 0.5740 mL | 1.4350 mL | |
| 60 mM | 0.0478 mL | 0.2392 mL | 0.4783 mL | 1.1958 mL | |
| 80 mM | 0.0359 mL | 0.1794 mL | 0.3588 mL | 0.8969 mL |
Powered by Bioz